Creo Medical Group PLC (AIM:CREO) has announced the appointment of Marco Scarci as the company’s new Pulmonary Clinical Advisory Group lead.
Scarci will provide advice on the company’s microwave ablation technology, Creo said in a statement, which includes devices used to remove soft tissue such as nodules or tumours.
“I and many others believe this technology to be […] a potential game changer in the way soft tissue lesions can be treated in future,” Scarci said.
Scarci is a London-based thoracic consultant who specialises in minimally invasive techniques of surgery, having previously worked at the likes of the University of Toronto and Guy's and St Thomas' hospitals.
“Marco's extensive network will enable him to engage with […] partners, medical advisors, key opinion leaders and medical societies to help shape and take forward Creo's microwave ablation clinical strategy,” the company explained.
“It's fantastic to have such a globally respected mind helping guide us as we look to maximise the impact of our technology,” chief executive Craig Gulliford added.